Genomics|Genetic Testing|EGAPP Recommendations|UGT1A1 Colorectal Cancer

Genetic Testing
Should UGT1A1 Genotyping Be Used to Predict Response to Irinotecan Chemotherapy?
EGAPP™ Recommendation

Background
Irinotecan is a drug that is often used in combination with other chemotherapy agents to treat colorectal cancer that has spread to other parts of the body (metastatic). Certain changes in a gene known as UGT1A1 have been found to affect how quickly a person’s body metabolizes (changes) irinotecan from its active to inactive form. This could impact how much of the drug should be used (dosing), and the type and severity of side effects a person might experience.

Patients metabolize (or process) drugs differently because of a variety of factors. Variations in genes may be one reason why some people metabolize certain drugs well and other people do not. The EGAPP™ Working Group examined the scientific evidence to see whether UGT1A1 genotyping is valid and useful for guiding irinotecan dosing in the management of patients with metastatic colorectal cancer to improve effectiveness and reduce side effects.

open here to see the full-text:
Genomics|Genetic Testing|EGAPP Recommendations|UGT1A1 Colorectal Cancer